Page 17 - AN-3-2

Advanced Neurology Limbic-predominant TDP-43 encephalopathy

47. Jeon YM, Kwon Y, Lee S, et al. Vitamin B12 reduces TDP- 53. Oveisgharan S, Yu L, Agrawal S, et al. Relation of motor
43 toxicity by alleviating oxidative stress and mitochondrial impairments to neuropathologic changes of limbic-
dysfunction. Antioxidants (Basel). 2021;11(1):82. predominant age-related TDP-43 encephalopathy in older
adults. Neurology. 2023;101(15):e1542-e1553.
doi: 10.3390/antiox11010082
doi: 10.1212/WNL.0000000000207726
48. Nilaver BI, Urbanski HF. Mechanisms underlying TDP-43
pathology and neurodegeneration: An updated mini-review. 54. Winston CN, Sukreet S, Lynch H, et al. Evaluation of
Front Aging Neurosci. 2023;15:1142617. blood-based, extracellular vesicles as biomarkers for aging-
related TDP-43 pathology. Alzheimers Dement (Amst).
doi: 10.3389/fnagi.2023.1142617
2022;14(1):e12365.
49. Jo M, Lee S, Jeon YM, Kim S, Kwon Y, Kim HJ. The role
of TDP-43 propagation in neurodegenerative diseases: doi: 10.1002/dad2.12365
Integrating insights from clinical and experimental studies. 55. Bauer CE, Zachariou V, Sudduth TL, et al. Plasma TDP-43
Exp Mol Med. 2020;52(10):1652-1662. levels are associated with neuroimaging measures of brain
structure in limbic regions. Alzheimers Dement (Amst).
doi: 10.1038/s12276-020-00513-7
2023;15(2):e12437.
50. Jamerlan A, An SSA. The influence of Aβ-dependent
and independent pathways on TDP-43 proteinopathy in doi: 10.1002/dad2.12437
Alzheimer’s disease: A possible connection to LATE-NC. 56. Gal J, Vary C, Gartner CA, Jicha GA, Abner EL, Ortega
Neurobiol Aging. 2020;95:161-167. YS, Choucair I, Wilcock DM, Nelson R, Nelson P, et al.
Exploratory mass spectrometry of cerebrospinal fluid from
doi: 10.1016/j.neurobiolaging.2020.06.020
persons with autopsy-confirmed LATE-NC. Res Sq. 2023.
51. Tomé SO, Gawor K, Thal DR. LATE-NC in Alzheimer’s
disease: Molecular aspects and synergies. Brain Pathol. doi: 10.21203/rs.3.rs-3252238/v1
2023:e13213. 57. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in
early Alzheimer’s disease. N Engl J Med. 2022;388(1):9-21.
doi: 10.1111/bpa.13213
doi: 10.1056/NEJMoa2212948
52. Corriveau-Lecavalier N, Botha H, Graff-Radford J, Switzer
AR, Przybelski SA, Wiste HJ, et al. A limbic-predominant 58. Francois-Moutal L, Scott DD, Khanna M. Direct targeting of
amnestic neurodegenerative syndrome associated with TDP-43, from small molecules to biologics: The therapeutic
TDP-43 pathology. medRxiv 2023. landscape. RSC Chem Biol. 2021;2(4):1158-1166.
doi: 10.1101/2023.11.19.23298314 doi: 10.1039/d1cb00110h

Volume 3 Issue 2 (2024) 11 doi: 10.36922/an.2603